The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer

British Journal of Cancer

Volumn 106, Issue 1, 2012, Pages 61-69

  Goldstein, D ^a,b   Spry, N ^c,d   Cummins, M M ^e   Brown, C ^e   Van Hazel, G A ^c,d   Carroll, S ^a   Selva Nayagam, S ^f   Borg, M ^f   Ackland, S P ^g   Wratten, C ^g   Shapiro, J ^h   Porter, I W T ⁱ   Hruby, G ^j   Horvath, L ^j   Bydder, S ^c,d   Underhill, C ^k   Harvey, J ^l   Gebski, V J ^e  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g NEWCASTLE MATER HOSPITAL   (Australia)

^h CABRINI INSTITUTE   (Australia)

ⁱ ALFRED HOSPITAL   (Australia)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^k Border Medical Oncology Australia   (Australia)

^l PRINCESS ALEXANDRA HOSPITAL   (Australia)

more..

Author keywords

chemoradiotherapy; conformal radiotherapy; locally advanced; pancreas cancer; unresectable

Indexed keywords

FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; INFECTION; LOCALLY ADVANCED PANCREATIC CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SIDE EFFECT; STOMACH HEMORRHAGE; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84855341067     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.526     Document Type: Article

References (41)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376 (Pubitemid 23073154)
2. Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 1(11): 710-719 (Pubitemid 14202071)
3. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson 3rd AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20(15): 3270-3275 (Pubitemid 34831525)
4. Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, Loehrer P (2006) Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 11(6): 612-623 (Pubitemid 43967616)
5. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19(9): 1592-1599
6. Chung HW, Bang SM, Park SW, Chung JB, Kang JK, Kim JW, Seong JS, Lee WJ, Song SY (2004) A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemor-adiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60(5): 1494-1501 (Pubitemid 39601866)
7. Cohen SJ, Dobelbower Jr R, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG (2005) A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62(5): 1345-1350 (Pubitemid 40982053)
8. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19): 1817-1825
9. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V (2010) Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 21(3): 441-447
10. Earle JD, Foley JF, Wieand HS, Kvols LK, McKenna PJ, Krook JE, Tschetter LK, Schutt AJ, Twito DI (1994) Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 28(1): 207-211 (Pubitemid 24012873)
11. Ebert MA, Haworth A, Kearvell R, Hooton B, Coleman R, Spry N, Bydder S, Joseph D (2008) Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system. Radiother Oncol 86(2): 200-210
12. El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA (2003) Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 21(15): 2920-2925 (Pubitemid 46621842)
13. Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, Buchler MW, Dervenis C, Fernandez Cruz L, Friess H, Grahm AL, Jeekel J, Laugier R, Meyer D, Singer MW, Tihanyi T (1999) Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer 35(6): 939-941 (Pubitemid 29277128)
14. GITSG (1985) Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer 56(11): 2563-2568
15. GITSG (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80(10): 751-755
16. Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M, Shapiro J, Davies T, Reece W, Harvey J, Spry N (2007) Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 97(4): 464-471 (Pubitemid 47258454)
17. Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A, MacFarlane JK (1981) Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 32(3): 164-165 (Pubitemid 12231867)
18. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, Den iaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25(3): 326-331 (Pubitemid 350003022)
19. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D (2009) Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27(13): 2269-2277
20. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55(1): 10-30 (Pubitemid 40310185)
21. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28(22): 3617-3622
22. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 3(3): 373-378 (Pubitemid 15132005)
23. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA (2007) A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 68(3): 809-816 (Pubitemid 46818742)
24. Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, Chang FY, Lee SD, Yen SH (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57(1): 98-104 (Pubitemid 36959744)
25. Loehrer Sr PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, Crane CH, Alberts SR, Benson III AB (2008) A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 26: (Suppl)15s (abstract 4506)
26. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23(15): 3509-3516
27. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas Jr HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 48(8): 1705-1710 (Pubitemid 11022870)
28. Moureau-Zabotto L, Phelip JM, Afchain P, Mineur L, Andre T, Vendrely V, Lledo G, Dupuis O, Huguet F, Touboul E, Balosso J, Louvet C (2008) Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol 26(7): 1080-1085
29. Osborne C, Bydder SA, Ebert MA, Spry NA (2006) Comparison of non-coplanar and coplanar irradiation techniques to treat cancer of the pancreas. Australas Radiol 50(5): 463-467 (Pubitemid 44386512)
30. Osoba D (2002) A taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results. Med Care 40(6): III31-III38
31. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD (2010) Phase III Study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J Clin Oncol 28(22): 3605-3610
32. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson 3rd AB (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27(23): 3778-3785
33. Rocha Lima CM, Green MR, Rotche R, Miller Jr WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22(18): 3776-3783 (Pubitemid 41095218)
34. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14(5): 1545-1551 (Pubitemid 26134212)
35. Shinchi H, Takao S, Noma H, Matsuo Y, Mataki Y, Mori S, Aikou T (2002) Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53(1): 146-150 (Pubitemid 34465818)
36. Spry N, Harvey J, Macleod C, Borg M, Ngan SY, Millar JL, Graham P, Zissiadis Y, Kneebone A, Carroll S, Davies T, Reece WH, Iacopetta B, Goldstein D (2008) 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. Int J Radiat Oncol Biol Phys 70(5): 1438-1446
37. Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, Wyld D, Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB, Simes RJ (2007) Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol 8(7): 603-612 (Pubitemid 46995622)
38. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27(13): 2231-2237
39. Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, Flentje M, Miethe S, Boettcher HD, Scholten T, Bruns CJ, Rau HG, Hinke A, Heinemann V (2009) Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer-a multi-centre randomised phase II study. Br J Cancer 101(11): 1853-1859
40. Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V (2006) Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP 7(4): 349-360 (Pubitemid 44083106)
41. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA (2008) Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 37(3): 269-274